Articles related to DEPRESSION

Aripiprazole supplementation of existing antidepressants in older adults with treatment-resistant depression significantly improved wellbeing over 10 weeks compared to switching to bupropion, and it was also associated with a numerically higher incidence of remission. Changes in wellbeing and the occurrence of remission with lithium augmentation or a switch to nortriptyline were comparable among patients in whom augmentation or a switch to bupropion failed.

The study included 186 patients who had recently been diagnosed with advanced lung cancer (Stage IV). Investigators were curious about the relationship between depression levels and systemic inflammation ratio (SIR) biomarker levels at diagnosis. SIRs are made up of three biomarkers that are linked to inflammation in the body, which has been linked to lower survival rates. All participants also filled out a depression questionnaire. According to the findings, 35% of patients had moderate to severe depressive symptoms.

The study enrolled 581 adult outpatients with DSM-5-diagnosed MDD, HDRS-17>=22, and >=32 on the Montgomery-Asberg Depression Rating Scale. Patients were randomly assigned to receive zuranolone 20 mg, 30 mg, or placebo for 14 days, followed by an observation period (days 15-42) and an extended follow-up period (days 43–182). The primary endpoint in HDRS-17 at day 15 was change from baseline (CFB). MOUNTAIN did not meet its primary endpoint, but there were significant rapid improvements in depressive symptoms with zuranolone 30 mg at days 3, 8, and 12, and it was generally well tolerated in patients with MDD.

Social isolation and loneliness were linked to a 17% to 19% increased risk of developing incipient heart failure, respectively. The analysis included 464,773 participants from the U.K. Biobank, followed for a median of 12.3 years.

This observational study compared IV ketamine (47) to IN esketamine (15) in 62 adults suffering treatment-resistant depression. Response was measured using the QIDS-SR tool. The results? The two formulations were comparable in terms of change between baseline and endpoint QIDS-SR and response rates. However, IV ketamine generated benefits with fewer treatments.

The updated guidelines recommend, in brief: